HURA TuHURA Biosciences, Inc.

NASDAQ
$2.10

TuHURA Biosciences, Inc. (HURA) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.3% since its last earnings release on August 14, 2026.

TuHURA Biosciences Beat Consensus Estimates
Friday, August 14, 2026 · 7:45 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 7:45 AM ET
Earnings Whisper
-
vs ($0.14)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.13

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About TuHURA Biosciences, Inc.

TuHURA Biosciences Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA Biosciences Inc., formerly known as Kintara Therapeutics Inc., is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.